Advanced search
Publication Cover
Journal of Medical Economics Volume 16, 2013 - Issue 2
Submit an article Journal homepage
609
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors

Saurabh RayAbbott Laboratories Abbott Park, ILUSA
,
Vijayveer BonthapallyAbbott Laboratories Abbott Park, ILUSA
,
Kyle D. HolenAbbott Laboratories Abbott Park, ILUSA
,
Geneviève GauthierAnalysis Group, Inc. Boston, MAUSA
,
Eric Q. WuAnalysis Group, Inc. Boston, MAUSA
,
Martin CloutierAnalysis Group, Inc. Boston, MAUSA
&
Annie GuérinAnalysis Group, Inc. Boston, MAUSACorrespondence[email protected]
 show all
Pages 221-230 | Accepted 09 Nov 2012, Published online: 27 Nov 2012

References

  • National Cancer Institute. A snapshot of colorectal cancer. http://www.cancer.gov/aboutnci/servingpeople/cancer-statistics/snapshots. Accessed September 19, 2012
  • National Cancer Institute, A Snapshot of Lung Cancer. 2012. http://www.cancer.gov/aboutnci/servingpeople/cancer-statistics/snapshots. Accessed September 19. 2012
  • National Cancer Institute. SEER stat fact sheets: colon and rectum. 2012. http://www.cancer.gov/statfacts/html/colorect.html. Accessed September 19, 2012
  • National Cancer Institute. SEER stat fact sheets: lung and bronchus. 2012. http://www.cancer.gov/statfacts/html/lungb.html. Accessed September 19, 2012
  • National Cancer Institute. A snapshot of head & neck and thyroid cancers. 2012. http://www.cancer.gov/aboutnci/servingpeople/snapshots/head-neck.pdf. Accessed September 19, 2012
  • Chang A, Parikh P, Thongprasert A, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL Study. J Thorac Oncol 2006;1:847-55
  • Cutsem E, Peeters M, Siena S, et al. Open-Label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64
  • Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79
  • Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors [abstract]. Target Oncol 2009;4:107-19
  • Gridelli C, Maione P, Amoroso D, et al. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. Crit Rev Oncol/Hematol 2008;66:155-62
  • Abraham T, Rademaker West D, Lacouture M, et al. Economic impact in the management of dermatologic adverse drug reactions induced by the Epidermal Growth Factor Receptor Inhibitor (EGFRI) Erlotinib [abstract]. J Am Acad Dermatol 2009;66(3):AB55
  • Mittmann N, Seung SJ. Rash rates with egfr inhibitors: meta-analysis. Curr Oncol 2011;18:e52-e63
  • Borovicka J, Calahan C, Gandhi M, et al. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. Arch Dermatol 2011;147:1403-9
  • Tan EH, Chan A. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother 2009;43:1658-66
  • Lacouture M. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Rev Cancer 2006;6:803-12
  • Mittman N, Seung SJ. Rash rates with EGFR Inhibitors: meta-analysis. Curr Oncol 2011;18:e54-e63
  • Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-21
  • Melosky B, Burkes R, Rayson D, et al. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009;16:14-24

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.